GPCR Stock — Structure Therapeutics Inc.: Cash, EV, Pipeline

What they do

We are a clinical stage global biopharmaceutical company developing novel oral small molecule therapeutics to treat a wide range of chronic diseases with unmet medical need. Our differentiated technology platform leverages both structure-based drug discovery and our expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (“GPCRs”).

Source: 10-K FY2025 via SEC EDGAR

Share price

$20.35

Market cap

$1,451.2M

Cash

$1,342.7M

Enterprise value

$108.5M

Balance sheet

Cash	$1,342.7M
Debt	$0.0M
Net cash	$1,342.7M
Enterprise value	$108.5M
Basic shares	71.3M shares
Fully diluted shares	82.0M shares
Fully diluted market cap	$1,668.6M
Cash per share	$18.83
Quarterly burn	$120.1M
Cash runway	11.2 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

71.3M

Pre-funded warrants

1.5M

Options

5.7M

RSUs

2.1M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

1.3M

FDSO

82.0M

Cap table as of 2026-06-30.

Price history

Loading GPCR daily closes…

Loading price history…

Next catalyst

Aleniglipron · Now - Nov 24, 2026 Now · Phase 2 · Obese; Obesity; Obesity Type 2 Diabetes Mellitus

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Now - Nov 24, 2026 Now	Aleniglipron	Phase 2	Obese; Obesity; Obesity Type 2 Diabetes Mellitus	Q4 2026 Est. Nov 15, 2026 · quarter midpoint
GUIDEDEst. Nov 15, 2026 Now quarter midpoint	aleniglipron Phase 2 Body Composition · NCT07169942	Phase 2	Not disclosed	Q4 2026
GUIDEDEst. Nov 15, 2026 Now quarter midpoint	aleniglipron Phase 1 SWITCH	Phase 1	Not disclosed	Q4 2026
Apr 12 - May 24 in 5 mo	ACCG-2671	Phase 2	Obesity	1H 2027 Est. Apr 1, 2027 · half midpoint
Oct 13 - Nov 24 in 24 mo	Aleniglipron	Phase 3	Obesity; Overweight; Chronic Weight Management	—
Oct 13 - Nov 24 in 24 mo	aleniglipron	Phase 3	Obesity; Overweight; Chronic Weight Management	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

aleniglipron

Phase 3 · Active Modality: small molecule (oral, once-daily)

Aliases GSBR-1290

Target GLP-1R

Partnerships Schrodinger (co-founder and strategic discovery partner); Genentech/Roche (December 2025 non-exclusive license to a different class of oral GLP-1R agonist patents; $100M upfront)

Indications

Obesity, overweight and related conditions (Phase 3)

Catalysts

— third quarter of 2026
— second half of 2026
— second half of 2026
— second half of 2026

Status note Most advanced candidate; Phase 3 ACCOMPLISH program (two trials) initiated August 2026 following end-of-Phase-2 correspondence with FDA.

ACCG-2671

Phase 1 · Active Modality: small molecule (oral)

Target amylin receptor

Partnerships Schrodinger (discovery collaboration)

Indications

Obesity (Phase 1)

Catalysts

— third quarter of 2026

Status note Lead oral amylin receptor agonist candidate; Phase 1 initiated December 2025.

ACCG-3535

Preclinical · Active Modality: small molecule (oral)

Target amylin receptor

Partnerships Schrodinger (discovery collaboration)

Indications

Obesity (Preclinical)

Catalysts

— fourth quarter of 2026

Status note Second oral amylin development candidate, selected November 2025.

LTSE-2578

Phase 1 · Active Modality: small molecule (oral)

Target LPA1R

Partnerships Schrodinger (discovery collaboration via Lhotse Bio)

Indications

Idiopathic pulmonary fibrosis (IPF) (Phase 1)

Status note Phase 1 single- and multiple-ascending-dose trial completed July 2025; company is considering strategic alternatives for the Phase 2-ready program in non-metabolic indications.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Aleniglipron
Lead indication	Obesity; Overweight; Chronic Weight Management
Lead phase	Phase 3
Active trials	5
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07654361	Phase 3	Recruiting	Sponsor	GPCR	—	Obesity; Overweight; Chronic Weight Management	—
NCT07654374	Phase 3	Recruiting	Sponsor	GPCR	—	Obesity; Overweight; Chronic Weight Management	—
NCT07815678	Phase 2	Recruiting	Sponsor	GPCR	—	Obesity	1H 2027 Est. Apr 1, 2027 · half midpoint
NCT07169942	Phase 2	Active, not recruiting	Sponsor	GPCR	—	Obesity, Overweight, or Chronic Weight Management	Q4 2026 Est. Nov 15, 2026 · quarter midpoint
NCT07400588	Phase 2	Active, not recruiting	Sponsor	GPCR	—	Obese; Obesity; Obesity Type 2 Diabetes Mellitus	Q4 2026 Est. Nov 15, 2026 · quarter midpoint
NCT04558450	Not disclosed	Recruiting	Collaborator	Assistance Publique - Hôpitaux de Paris	—	Covid19; Arterial Stiffness; Endothelial Dysfunction	—

Sponsor-matched active trials from ClinicalTrials.gov (5 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 6 active trials for Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Avoro Capital Advisors	6,555,555	no change	3.16%	2026-08-14
BVF Partners	3,366,823	-92,535	4.62%	2026-08-14
OrbiMed Advisors	2,209,400	+733,997	2.25%	2026-08-14
RTW Investments	1,607,507	+1,607,507	0.74%	2026-08-14
Baker Bros. Advisors	1,432,529	no change	0.39%	2026-08-14
Casdin Capital	1,175,000	no change	3.16%	2026-08-14
Deerfield Management	1,086,000	+318,007	0.61%	2026-08-14
Logos Global Management	500,000	no change	1.16%	2026-08-14
Boxer Capital	75,000	no change	0.30%	2026-08-14
Cormorant Asset Management	75,000	-100,000	0.21%	2026-08-14
DAFNA Capital	46,500	no change	0.48%	2026-08-14
Sphera Biotech	28,600	-22,200	0.22%	2026-08-14
ADAR1 Capital Management	17,500	+17,500	0.04%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

GPCR — Structure Therapeutics Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

GPCR — Structure Therapeutics Inc.